Piramal Pharma Scores Higher on 2025 S&P Global Sustainability Assessment

Piramal Pharma Limited (PPL) has achieved a significant score increase on the 2025 S&P Global Corporate Sustainability Assessment (CSA), reaching 63. This marks a 15% improvement from last year's score of 55, placing the company in the 91st percentile within the pharmaceutical industry. The S&P Global CSA is a respected framework that evaluates sustainability practices globally, focusing on environmental, social, and governance (ESG) criteria.

PPL's enhanced score reflects its commitment to sustainability through a four-pillar approach: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. This strategy supports responsible operations that benefit partners, patients, and the environment. CEO Peter DeYoung remarked on their dedication to sustainable growth and excellence, promising continued advancements based on CSA insights.